Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

L.A. McKeown

March 31, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2024

SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve

L.A. McKeown

April 07, 2024

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Todd Neale

March 05, 2023

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

L.A. McKeown

April 07, 2020

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Michael O'Riordan

April 07, 2016

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

Advertisement

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content